Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 20.
doi: 10.1007/s00347-025-02345-0. Online ahead of print.

[CRIMSON : A multicentre randomised, sham-controlled, double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderate to severe non-proliferative diabetic retinopathy]

[Article in German]
Katrin Lorenz  1 , Tobias Peters  2 , Frank G Holz  3 ; DOG AG Klinische Studienzentren
Collaborators, Affiliations

[CRIMSON : A multicentre randomised, sham-controlled, double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderate to severe non-proliferative diabetic retinopathy]

[Article in German]
Katrin Lorenz et al. Ophthalmologie. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Einhaltung ethischer Richtlinien. Interessenkonflikt: K. Lorenz, T. Peters und F.G. Holz geben an, dass für alle in dieser Publikation genannten Studienzentren Prüferhonorare gezahlt wurden. Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

References

Literatur

    1. Wykoff CC, Yu HJ, Avery RL et al (2022) Retinal non-perfusion in diabetic retinopathy. Eye 36:249–256 - PubMed - PMC
    1. Silva PS, Marcus DM, Liu D, DRCR Retina Network (2022) Association of ultra-widefield fluorescein angiography-identified retinal nonperfusion and the risk of diabetic retinopathy worsening over time. JAMA Ophthalmol 14010:936–945
    1. Waheed NK, Rosen RB, Jia Y, Munk MR, Huang D, Fawzi A, Chong V, Nguyen QD, Sepah Y, Pearce E (2023) Optical coherence tomography angiography in diabetic retinopathy. Prog Retin Eye Res 97:101206. https://doi.org/10.1016/j.preteyeres.2023.101206 - PubMed - PMC
    1. Wykoff CC, Nittala MG, Villanueva Boone C, Yu HJ, Fan W, Velaga SB, Ehlers JP, Ip MS, Sadda SR, RECOVERY Study Group (2022) Final outcomes from the randomized RECOVERY trial of aflibercept for retinal nonperfusion in proliferative diabetic retinopathy. Ophthalmol Retin 6(7):557–566. https://doi.org/10.1016/j.oret.2022.02.013
    1. Zippel N, Kenny CH, Wu H et al (2022) Sema3A antibody BI‑X prevents cell permeability and cytoskeletal collapse in HRMECs and increases tip cell density in mouse oxygen-induced retinopathy. Transl Vision Sci Technol 11(6):17